These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 36493798)

  • 1. Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with
    Bewersdorf JP; Patel KK; Goshua G; Shallis RM; Podoltsev NA; Stahl M; Stein EM; Huntington SF; Zeidan AM
    Leuk Lymphoma; 2023 Feb; 64(2):454-461. PubMed ID: 36493798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of venetoclax and ivosidenib/enasidenib for unfit newly diagnosed patients with acute myeloid leukemia and
    Wang L; Song J; Xiao X; Li D; Liu T; He X
    J Chemother; 2024 May; 36(3):202-207. PubMed ID: 37599456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness Analysis of Venetoclax in Combination with Azacitidine Versus Azacitidine Monotherapy in Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy: From a US Third Party Payer Perspective.
    Pratz KW; Chai X; Xie J; Yin L; Nie X; Montez M; Iantuono E; Downs L; Ma E
    Pharmacoeconomics; 2022 Aug; 40(8):777-790. PubMed ID: 35696071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Venetoclax in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: A Canadian Cost-Utility Analysis.
    Guinan K; Mathurin K; Au Y; Schuh AC; Bui CN; Chai X; Lachaine J
    Curr Oncol; 2022 Oct; 29(10):7524-7536. PubMed ID: 36290869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Azacitidine for Treating Acute Myeloid Leukaemia with More Than 30 % Bone Marrow Blasts: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal.
    Tikhonova IA; Hoyle MW; Snowsill TM; Cooper C; Varley-Campbell JL; Rudin CE; Mujica Mota RE
    Pharmacoeconomics; 2017 Mar; 35(3):363-373. PubMed ID: 27752999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDA Approval Summary: Ivosidenib in Combination with Azacitidine for Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation.
    Woods A; Norsworthy KJ; Wang X; Vallejo J; Chiu Yuen Chow E; Li RJ; Sun J; Charlab R; Jiang X; Pazdur R; Theoret MR; de Claro RA
    Clin Cancer Res; 2024 Apr; 30(7):1226-1231. PubMed ID: 38010220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ivosidenib and Azacitidine in
    Montesinos P; Recher C; Vives S; Zarzycka E; Wang J; Bertani G; Heuser M; Calado RT; Schuh AC; Yeh SP; Daigle SR; Hui J; Pandya SS; Gianolio DA; de Botton S; Döhner H
    N Engl J Med; 2022 Apr; 386(16):1519-1531. PubMed ID: 35443108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
    Edlin R; Connock M; Tubeuf S; Round J; Fry-Smith A; Hyde C; Greenheld W
    Health Technol Assess; 2010 May; 14 Suppl 1():69-74. PubMed ID: 20507806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cost-effectiveness of glasdegib in combination with low-dose cytarabine, for the treatment of newly diagnosed acute myeloid leukemia in adult patients who are not eligible to receive intensive induction chemotherapy in Canada.
    Hu Y; Charaan M; van Oostrum I; Heeg B; Bell T
    J Med Econ; 2021; 24(1):150-161. PubMed ID: 33461352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia.
    DiNardo CD; Stein AS; Stein EM; Fathi AT; Frankfurt O; Schuh AC; Döhner H; Martinelli G; Patel PA; Raffoux E; Tan P; Zeidan AM; de Botton S; Kantarjian HM; Stone RM; Frattini MG; Lersch F; Gong J; Gianolio DA; Zhang V; Franovic A; Fan B; Goldwasser M; Daigle S; Choe S; Wu B; Winkler T; Vyas P
    J Clin Oncol; 2021 Jan; 39(1):57-65. PubMed ID: 33119479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies.
    Lachowiez CA; Loghavi S; Zeng Z; Tanaka T; Kim YJ; Uryu H; Turkalj S; Jakobsen NA; Luskin MR; Duose DY; Tidwell RSS; Short NJ; Borthakur G; Kadia TM; Masarova L; Tippett GD; Bose P; Jabbour EJ; Ravandi F; Daver NG; Garcia-Manero G; Kantarjian H; Garcia JS; Vyas P; Takahashi K; Konopleva M; DiNardo CD
    Blood Cancer Discov; 2023 Jul; 4(4):276-293. PubMed ID: 37102976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia.
    Patel KK; Zeidan AM; Shallis RM; Prebet T; Podoltsev N; Huntington SF
    Blood Adv; 2021 Feb; 5(4):994-1002. PubMed ID: 33591323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of azacitidine maintenance therapy in patients with acute myeloid leukemia.
    Zhu J; Wu Q; Wang J; Niu T
    Expert Rev Hematol; 2022 Apr; 15(4):375-382. PubMed ID: 35437111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States.
    Shah BD; Smith NJ; Feng C; Jeyakumar S; Castaigne JG; Faghmous I; Masouleh BK; Malone DC; Bishop MR
    Adv Ther; 2022 Aug; 39(8):3678-3695. PubMed ID: 35727476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ivosidenib and Azacitidine in IDH1-Mutated AML.
    Gil-Sierra MD; Briceño-Casado MP; Sierra-Sanchez JF
    N Engl J Med; 2022 Jun; 386(26):2535-2536. PubMed ID: 35767448
    [No Abstract]   [Full Text] [Related]  

  • 16. Ivosidenib and Azacitidine in IDH1-Mutated AML.
    Goodman AM; Mohyuddin GR; Prasad V
    N Engl J Med; 2022 Jun; 386(26):2536. PubMed ID: 35767449
    [No Abstract]   [Full Text] [Related]  

  • 17. Ivosidenib and Azacitidine in IDH1-Mutated AML. Reply.
    Montesinos P; de Botton S; Döhner H
    N Engl J Med; 2022 Jun; 386(26):2536-2537. PubMed ID: 35767450
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost Effectiveness of Midostaurin in the Treatment of Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in the United States.
    Stein E; Xie J; Duchesneau E; Bhattacharyya S; Vudumula U; Ndife B; Bonifacio G; Guerin A; Li N; Joseph G
    Pharmacoeconomics; 2019 Feb; 37(2):239-253. PubMed ID: 30382485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.
    DiNardo CD; Schuh AC; Stein EM; Montesinos P; Wei AH; de Botton S; Zeidan AM; Fathi AT; Kantarjian HM; Bennett JM; Frattini MG; Martin-Regueira P; Lersch F; Gong J; Hasan M; Vyas P; Döhner H
    Lancet Oncol; 2021 Nov; 22(11):1597-1608. PubMed ID: 34672961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is Induction of Hypomethylation with Ivosidenib and 5-Azacitidine Curative Regimen against IDH1-Mutated Acute Myeloid Leukemia?
    Takahashi K
    Anticancer Agents Med Chem; 2023; 23(8):864-866. PubMed ID: 36503457
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.